Bristol Myers Squibb stock heads into the open after a 1.0% drop
Published on 09/11/2026 at 07:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock closed at USD 63.75 on the NYSE on September 10, 2026, slipping 1.02 percent versus the prior session per Zacks and Nasdaq data. Compared with the broader U.S. market, the shares fell more than the S&P 500, which also ended lower on September 10, 2026.
September 10, 2026 in numbers
Bristol Myers Squibb Inc. (ISIN US0897961004, NYSE: BMY) was reported by Zacks to have declined 1.02 percent to USD 63.75 at the close on September 10, 2026, underperforming the S&P 500 in that session. Per options flow data summarized by MarketBeat on September 10, 2026, investors bought a large volume of put options on Bristol Myers Squibb that day, signaling increased demand for downside protection and helping explain part of the selling pressure in the stock.
The same MarketBeat report noted Bristol Myers Squibb shares trading near USD 63.76 during the September 10, 2026 session, consistent with the NYSE close and within a 52-week range reported by Ad-hoc-news between USD 42.52 and USD 68.64, leaving the stock in the upper portion of its one-year band on September 9, 2026. As Ad-hoc-news highlighted on September 10, 2026, Bristol Myers Squibb stock closed at USD 64.69 on the NYSE on September 9, 2026, marking a 3.19 percent decline versus the previous day but still near the upper third of that 52-week corridor, which means the September 10, 2026 close around USD 63.75 kept the shares only modestly below recent levels in that range.Ad-hoc-news According to Ad-hoc-news citing MarketWatch data, the 52-week range stood between USD 42.52 and USD 68.64 as of September 9, 2026, so the USD 63.75 close on September 10, 2026 left the stock roughly USD 4.89 below its 52-week high.
Today’s drivers and calendar
Options positioning and analyst commentary continue to frame sentiment for Bristol Myers Squibb today. MarketBeat reported on September 10, 2026 that Bristol Myers Squibb has full-year 2026 earnings guidance of USD 6.75 to USD 7.00 per share and that analysts expect about USD 6.95 per share for the current year, reinforcing a moderately bullish stance with an average price target of USD 66.33 compared with the recent price near USD 63.75.MarketBeat In a separate analyst update on September 10, 2026, The Globe and Mail, citing TipRanks data, noted that BMO Capital maintained a Hold rating on Bristol Myers Squibb with a USD 60.00 price target, while the broader analyst consensus pointed to a Moderate Buy and an average target near USD 66.94, which investors may weigh heading into today’s session.The Globe and Mail
No new company earnings release or major scheduled event specific to Bristol Myers Squibb is set for September 11, 2026 in the latest earnings calendar snapshots, so attention today is likely to remain on how the stock trades relative to its recent guidance discussion, analyst targets and the wider healthcare sector as U.S. indices look to stabilize after their September 10, 2026 declines.Yahoo Finance
